Emyria Ltd (ASX:EMD) medical director Alistair Vickery has demonstrated his faith in the company’s biotechnology strategy with the purchase of shares in an on-market transaction.
Vickery acquired 128,000 shares on October 19, and this was his first purchase of fully paid ordinary shares in the company, formerly known as Emerald Clinics.
Partnering with New York’s Mt Sinai Hospital
In September, the company entered a professional services agreement with the Precision Recovery team at New York’s Mt Sinai Hospital, one of the USA's leading teaching and research hospitals, to support ongoing development of Emerald’s Openly clinical service.
The Precision Recovery Team is currently managing over 1,600 COVID-positive, COVID-suspected and COVID-recovering individuals remotely and has special expertise in this area.
Under the agreement, Mt Sinai’s Precision Recovery team will provide remote monitoring and consulting services to support the development and delivery of Emerald’s Openly clinical service worldwide, in exchange for access to the Openly app and a payment for any alert reviewed by the Mt Sinai team on request.